A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Trial Profile

A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Liposarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results assessing the association between Neutropenia and response to Palbociclib in two phase II trials (NCT01037790 and NCT01209598) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 25 Apr 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016 as per ClinicalTrials.gov record.
    • 25 Apr 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top